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Introduction {#sec1}
============

Diabetic nephropathy (DN) is a severe microvascular complication of diabetes. DN presents as albuminuria, hypertension, renal injury, and finally, renal failure. Approximately 30--40% of patients with diabetes mellitus develop DN,[@bib1]^,^[@bib2] that can severely damage patients' physical and mental health, ultimately increasing the economic burden on society.[@bib3] In developed countries, such as the USA and Norway, DN was the major cause of end-stage renal diseases (ESRDs) until a decade ago.[@bib4] In China, with economic development and the change of lifestyles, DN has become the most common cause of ESRDs.[@bib1] Thus, increased attention has been paid to traditional Chinese medicine in the treatment of DN in recent years. Tripterygium glycosides (TGs) were the earliest traditional Chinese medicines that were used to treat DN; therefore, Chinese physicians have the most clinical experience of their use.

*Tripterygium wilfordii* Hook. F (TwHF) is a medicinal plant from the genera Tripterygium and the family Celastraceae. In addition, TwHF is used to treat chronic nephritis,[@bib5] active rheumatoid arthritis,[@bib6], [@bib7], [@bib8] and systemic lupus erythematosus,[@bib9] among others. TGs are extracted from TwHF, and can be used to regulate immunity, reduce blood sugar, or as anti-inflammatories.[@bib10]^,^[@bib11] TGs have also been used to treat proteinuria in patients with DN.[@bib12]^,^[@bib13] Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are common treatments for DN.[@bib14] In recent years, TGs have been used widely in China. However, randomized controlled trials (RCTs) are lacking, particularly those comparing treatment using ACE inhibitors or ARBs plus TGs with treatment using ACE inhibitors or ARBs alone. This meta-analysis only includes RCTs that examined the effectiveness and safety of adding TGs to ACE inhibitors or ARBs to treat patients with DN. The results will provide a basis for clinical use of TGs.

Methods {#sec2}
=======

The meta-analysis was performed according to the recommendations of the Cochrane handbook for systematic reviews of interventions.[@bib15]^,^[@bib16] It also was reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines.[@bib17]

Study selection {#sec2.1}
---------------

The inclusion criteria for this meta-analysis were: (1) Patients with DN with a urine protein filtration rate \> 20 μg/min or a quantitative 24-h urinary total protein (UTP) \> 0.15 g/d (stages 3--5 of DN); (2) one study group treated with ACE inhibitors or ARBs plus TGs; (3) another study group treated with ACE inhibitors or ARBs alone, regardless of dosage, type, or duration of treatment; (4) RCTs with a parallel or crossover design, in both English and Chinese languages, regardless of the use of a blinding method; and (5) studies including 24-h UTP levels as an observed indicator.

The exclusion criteria for this meta-analysis were: (1) Patients with other kidney diseases, such as IgA Nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis, or membranous nephropathy; (2) patients with other severe diseases that could influence the outcomes, such as severe heart failure, cancer, disseminated intravascular coagulation (DIC), or severe infection; or (3) literature with repetitive content.

Data Sources and Searches {#sec2.2}
-------------------------

This study used the Embase, MEDLINE, Cochrane Library, SINOMED, China National Knowledge Infrastructure, VIP Information/Chinese Scientific Journals, and WANFANG databases to search for relevant studies. The literature search included studies that were published between the establishment of the databases and July 31, 2018. We conducted electronic searches using expanded Medical Subject Headings (MeSH) terms and corresponding key words.

The search terms used were (MeSH expanded term "Diabetic Nephropathy" and key words "diabetic nephropathy") (MeSH expanded term "Angiotensin Receptor Antagonists" and key words "receptor antagonist\*") (MeSH expanded term "Angiotensin Converting Enzyme Inhibitors"), and (MeSH expanded term "tripterygium glycosides"). At the same time, the reference lists of included textbooks, all retrieved studies, review articles, and reports of academic congresses were checked manually. The comprehensive search strategy is shown in [Appendix A](#appsec1){ref-type="sec"}.

Data extraction and quality assessment {#sec2.3}
--------------------------------------

Two investigators (Fang JY and Yang Y) independently researched studies from the retrieved literature, based on the inclusion criteria, and extracted their analytical results and data. If the two investigators had differing opinions regarding the quality of a study, differences were resolved by a third investigator (Yu TY). Data were only included for consideration if a consensus was achieved among all three investigators.

Two investigators (Fang JY and Yang Y) independently assessed the risk of bias using the Cochrane risk-of-bias tool. Each trial was reviewed and scored as high risk of bias (if the answer was yes), low risk of bias (if the answer was no), or unclear (if there were insufficient details to allow a definite judgment), based on the following criteria: (1) Random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinded assessment of the outcome, (5) incomplete outcome data assessments, (6) selective outcome reporting, and (7) other bias.

Statistical analysis {#sec2.4}
--------------------

In this meta-analysis, the data and analytical results were extracted to compare the effects of ACE inhibitors or ARBs with the effects of ACE inhibitors or ARBs plus TGs on 24-h UTP and serum creatinine (SCr) levels in patients with DN. Analyses were performed using Review Manager software (version 5.3; The Cochrane Collaboration, Denmark). The weighted mean difference ((*WMD* = √*SD1*^2^ + *SD2*^2^ -- *SD1* × *SD2*); *SD1* = baseline endpoint of control group; *SD2* = baseline endpoint of experimental group) was used to evaluate the measured data. Tests for heterogeneity were performed using the *I*^2^ statistic and the χ^2^ test, in which *I*^2^ \> 50% indicated significant heterogeneity and *I*^2^ \< 50% indicated minor heterogeneity.[@bib18] If the data showed greater significant heterogeneity, subgroup (meta-regression) or sensitivity analysis were used. A *P* value \< 0.05 was considered statistically significant. Both fixed and random-effect models were used in the meta-analysis; publication bias was assessed using funnel plots and evaluated using Begg\'s or Egger\'s tests.

Trial sequential analysis {#sec2.5}
-------------------------

To evaluate whether the present meta-analysis had a sufficient sample size to reach firm conclusions about the effects of the interventions, we used trial sequential analysis (TSA) for the outcomes. Traditionally, interim analysis of a single trial evaluates whether the monitoring boundaries for a predefined estimated effect are reached before the optimal sample size has been accrued. TSA performs a cumulative meta-analysis, which creates a Z-curve of the cumulative number of included patients and events, and the monitoring boundaries for benefit and harm, and estimates the optimal sample size. A sufficient level of evidence for the anticipated intervention effect might have been reached when the cumulative 8 Z-curve crosses the trial sequential monitoring boundary. If the Z-curve does not reach any of the boundaries and the required information size has not been reached, there is insufficient evidence to reach a conclusion. We used TSA software, version 0.9 Beta (Copenhagen Trial Unit, Denmark) for these analyses.

Results {#sec3}
=======

Background information on the included studies {#sec3.1}
----------------------------------------------

Electronic and manual searches yielded 1678 possibly relevant papers: 2 from Embase, 4 from MEDLINE®, 6 from the Cochrane Library, 347 from SINOMED, 556 from China National Knowledge Infrastructure, 196 from VIP Information/Chinese Scientific Journals, 546 from WANFANG, and 21 from manual searching. After removing duplicated publications, 565 papers remained. Of those, 156 papers were selected after review of their titles and abstracts. After reviewing the full text of each publication, 57 papers were selected. Based on the exclusion criteria, nine papers,[@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27] with 851 patients, were included in the final meta-analysis. This selection process is shown in [Fig. 1](#fig1){ref-type="fig"} Detailed information on the included studies is provided in [Table 1](#tbl1){ref-type="table"}, and an overview of the baseline characteristics of the study participants is shown in [Table 2](#tbl2){ref-type="table"}.Fig. 1Flow diagram of study identification process, and the inclusion and exclusion criteria.Fig. 1Table 1Characteristics of randomized controlled trials included in the meta-analysis.Table 1ReferencesProvinceACEI/ARBsACEI/ARBs + TGTrial durationSample sizeStudy designPrimary outcomeDropoutChen 2012[@bib19]XizangErbesartan 150 mg qdErbesartan 150 mg qd; TG 40 mg qd3 months50Random number table24-h UTP SCr0Song 2005[@bib20]ShandongBenazepril 5--20 mg qdBenazepril 5--20 mg qd; TG 1--2 mg/kg qd6 months67Lottery24-h UTP SCr0He 2016[@bib21]GuizhouBenazepril 5 mg bidBenazepril 5 mg bid; TG 0.3--0.5 mg/kg bid/tid2 months70Random number table24-h UTP0Zhang 2012[@bib22]GuangzhouErbesartan 75 mg bidErbesartan 75 mg bid; TG 10--20 mg tid6 months100Envelope method24-h UTP SCr0Tu 2017[@bib23]ZhejiangTelmisartan 40 mg qdTelmisartan 40 mg qd; TG 1.5 mg/kg tid1 months216Random number table24-h UTP SCr0Wu 2018[@bib24]ZhejiangValsartan 80--160 mg qdValsartan 40--80 mg qd; TG 10--20 mg tid6 months68Random number table24-h UTP SCr0Zhang 2016[@bib25]HebeiValsartan 80 mg qdValsartan 80 mg qd; TG 30 mg bid12 months140Random number table24-h UTP SCr9[a](#tbl1fna){ref-type="table-fn"}Li 2015[@bib26]BeijingErbesartan 150 mg qdErbesartan 150 mg qd; TG 40 mg qd6 months60Random number table24-h UTP SCr3[b](#tbl1fnb){ref-type="table-fn"}Song 2014[@bib27]HenanValsartan 40--80 mg qdValsartan 40--80 mg qd; TG 20 mg tid6 months80Random number table24-h UTP SCr0[^1][^2][^3]Table 2Baseline characteristics of participants included in the meta-analysis.Table 2ReferencesGroupGender (M/F)Mean ageUTP (g/24 h)SCr (μmol/L)BaselineEnd pointBaselineEnd pointChen 2012[@bib19]ACEI/ARBs11/1456.90 ± 12.108.57 ± 0.537.10 ± 0.79125.60 ± 29.42127.60 ± 31.3ACEI/ARBs + TG12/1357.30 ± 11.608.34 ± 1.296.42 ± 0.95131.12 ± 27.21129.6 ± 26.13Song 2005[@bib20]ACEI/ARBs22/1053.10 ± 11.301.65 ± 0.621.23 ± 0.5385.77 ± 19.1088.15 ± 17.13ACEI/ARBs + TG21/1450.10 ± 10.501.63 ± 0.510.88 ± 0.3183.15 ± 20.5670.56 ± 17.32He 2016[@bib21]ACEI/ARBs25/1058.50 ± 6.802.56 ± 0.571.97 ± 0.39----ACEI/ARBs + TG24/1157.80 ± 6.902.55 ± 0.571.38 ± 0.20----Zhang 2012[@bib22]ACEI/ARBs35/1554.23 ± 8.231.71 ± 0.151.25 ± 0.14125.90 ± 27.50118.30 ± 26.40ACEI/ARBs + TG33/1753.66 ± 7.801.73 ± 0.160.89 ± 0.12128.40 ± 27.60105.70 ± 22.70Tu 2017[@bib23]ACEI/ARBs62/4652.30 ± 6.301.44 ± 0.280.73 ± 0.24127.99 ± 25.44110.62 ± 20.35ACEI/ARBs + TG66/4251.20 ± 5.901.43 ± 0.290.47 ± 0.24126.96 ± 24.40101.31 ± 20.29Wu 2018[@bib24]ACEI/ARBs18/1655.00 ± 8.004.00 ± 1.703.00 ± 1.60137.00 ± 50.00125.00 ± 46.00ACEI/ARBs + TG19/1555.00 ± 9.004.00 ± 2.101.70 ± 1.20133.00 ± 51.00104.00 ± 42.00Zhang 2016[@bib25]ACEI/ARBs40/3059.82 ± 6.794.65 ± 2.933.50 ± 1.95199.70 ± 65.83235.96 ± 73.45ACEI/ARBs + TG46/2459.94 ± 6.534.68 ± 2.571.44 ± 1.03198.35 ± 63.94210.35 ± 68.50Li 2015[@bib26]ACEI/ARBs17/1356.12 ± 10.342.65 ± 1.322.29 ± 0.10147.31 ± 28.62145.25 ± 29.10ACEI/ARBs + TG16/1455.37 ± 9.972.74 ± 1.431.47 ± 0.69145.78 ± 24.79140.12 ± 23.16Song 2014[@bib27]ACEI/ARBs24/1650.33 ± 5.322.43 ± 1.041.98 ± 0.93101.42 ± 31.35105.32 ± 38.32ACEI/ARBs + TG22/1851.24 ± 5.772.54 ± 1.211.82 ± 0.89102.48 ± 29.45109.87 ± 41.43[^4]

Risk of bias {#sec3.2}
------------

The overall quality of the studies included in this investigation was not satisfactory; details on the risk-of-bias assessment are shown in [Fig. 2](#fig2){ref-type="fig"}. All nine RCTs used the random number acquisition method, but without a detailed description. Of the nine papers included, seven used a random number table, one used a lottery table, and one used the envelope method. None of the papers referred to the use of a blinded method ([Fig. 2](#fig2){ref-type="fig"}).Fig. 2Risk of bias graph: Each risk of bias item was included for each study.Fig. 2

Publication bias {#sec3.3}
----------------

Using the Begg\'s tests, no meta-analysis had a significant publication bias (24-h UTP: *P* \> 0.802, SCr: *P* \> 0.736) among all meta-analyses in the present study, as shown in [Fig. 3](#fig3){ref-type="fig"}.Fig. 3Publication bias analysis with funnel plots. a: Change in 24-h urinary total protein (24-h UTP); b: Change in serum creatinine (SCr) levels.Fig. 3

Effects on 24-h UTP levels {#sec3.4}
--------------------------

All the included studies reported the efficacy of ACE inhibitors or ARBs alone versus ACE inhibitors or ARBs plus TGs on 24-h UTP levels. We established three subgroups to distinguish between the effects of the length of treatment: Treatment \>6 months; treatment between 2 and 6 months; and treatment \<2 months. A comparison of the changes in 24-h UTP levels before and after treatment showed that the addition of TGs to the ACE inhibitor or ARB regimen produced significantly greater reductions in 24-h UTP levels in all three subgroups. The reduction in 24-h UTP levels in patients treated with ACE inhibitors or ARBs plus TGs might improve with increased treatment time. However, only one study used a treatment time \>6 months ([Fig. 4](#fig4){ref-type="fig"}).Fig. 4Forest plot for the change in 24-h urinary total protein (24-h UTP).Fig. 4

TSA of the nine comparisons illustrated that the cumulative Z curve crossed both the conventional boundary for benefit and the trial sequential monitoring boundary for benefit ([Fig. 5](#fig5){ref-type="fig"}).Fig. 5Trial sequential analysis (TSA) of 24-h urinary total protein (24-h UTP).Fig. 5

Effects on SCr levels {#sec3.5}
---------------------

Eight of the included studies reported the efficacy of ACE inhibitors or ARBs alone versus ACE inhibitors or ARBs plus TGs on SCr levels. A comparison of the changes in SCr levels before and after treatment showed that the addition of TGs to the ACE inhibitor or ARB regimen produced significantly greater reductions in SCr levels ([Fig. 6](#fig6){ref-type="fig"}).Fig. 6Forest plot for the change in serum creatinine (SCr).Fig. 6

TSA of the eight comparisons illustrated that the cumulative Z curve crossed both the conventional boundary for benefit and the trial sequential monitoring boundary for benefit ([Fig. 7](#fig7){ref-type="fig"}).Fig. 7Trial sequential analysis (TSA) of SCr.Fig. 7

Tolerability and safety {#sec3.6}
-----------------------

The major adverse effects of TGs include nausea, vomiting, liver injury, rash, and reproductive toxicity.[@bib28], [@bib29], [@bib30] Three of the included studies reported on the side effects of TGs during the treatment process. One article reported that, among those treated with ACE inhibitors or ARBs plus TGs, one patient had a headache and one had vasculitis. Among those treated with ACE inhibitors or ARBs alone, one patient reported a headache, one had vasculitis, and one had dry cough. Another paper reported that, among those treated with ACE inhibitors or ARBs plus TGs, two patients experienced liver injury, one had leukocyte reduction, and one had irregular menses. Among those treated with ACE inhibitors or ARBs alone, two patients reported hyperkalemia. In the studies by Wu et al[@bib24] and Zhang et al,[@bib22] two patients and three patients, respectively, appeared to have elevated levels of transaminase after using TGs. After stopping the use of TGs, their transaminase levels returned to normal. Another study reported that, among those treated with ACE inhibitors or ARBs plus TGs, one patient had a gastrointestinal reaction, three had liver injury, and one had leukocyte reduction. In terms of side effects, no statistical differences were observed between treatment with ACE inhibitors or ARBs plus TGs and ACE inhibitors or ARBs alone. All treatment drugs were well tolerated by nearly all the patients.

Discussion {#sec4}
==========

The results of this meta-analysis showed that the addition of TGs to the ACE inhibitor or ARB regimen provided better renal protective effects on albuminuria in patients with DN than treatment with ACE inhibitors or ARBs alone. Moreover, the addition of TGs to the ACE inhibitor or ARB regimen showed better results in terms of the reduction in SCr levels compared with that induced by ACE inhibitors or ARBs alone. There were no significant differences in the reported side effects between the two groups.

The pathogenesis of DN is multifactorial, and is often linked to hemodynamics, oxidative stress, inflammation, and, especially, the immune inflammatory response.[@bib10]^,^[@bib11]^,^[@bib31]^,^[@bib32] TGs are extracted from the traditional Chinese medicine, TwHF, which has been used to dispel wind and dampness, relieve swelling and pain, and promoting blood circulation to dredge collaterals. The active ingredients in TGs are diterpenoid alkaloids, as well as three terpenes.[@bib33] Some cell and animal experiments have shown that TGs can inhibit the expression of hypoxia-inducible factor 1-α, endothelin-1, and vascular endothelial growth factor in rats with DN to reduce inflammation, the number of mesangial cells, and mesangial matrix proliferation, thus delaying glomerulosclerosis.[@bib34]^,^[@bib35] Some studies have reported that TGs can intervene in nuclear factor-κB and toll-like receptor signaling pathways to reduce the production of tumor necrosis factor-α, interleukin-5, and immunoglobulin E, thus exerting immunosuppressive effects.[@bib13]^,^[@bib36] In addition, TGs can inhibit the proliferation of antigen-specific lymphocytes, reduce the deposition of antigen--antibody immune complexes, reduce the production of collagen fibers, and protect podocytes to reduce the degree of renal inflammation and delay damage to renal function.[@bib13]^,^[@bib37]^,^[@bib38] ACE inhibitors or ARBs are used commonly to treat DN, and can reduce urinary protein levels and improve renal function. However, we still lack a specific medication to treat DN, and the effects of treatment need to be improved. Thus, adding TGs to the ACE inhibitor or ARB regimen might represent an advance in DN treatment, especially in patients requiring long-term treatment. Although this meta-analysis did not show any differences in side effects between ACE inhibitors or ARBs plus TGs and ACE inhibitors or ARBs alone, some studies reported the side effects of TGs.[@bib28]^,^[@bib29] Thus, attention should be paid to this aspect during long-term treatment.

A meta-analysis in 2014 showed that treatment with ACE inhibitors or ARBs plus TGs had an better effect on patients with stage 4 DN compared to treatment with ACE inhibitors or ARBs alone.[@bib39] However, that study only included patients with stage 4 DN. Additionally, the meta-analysis included a quasi-RCT, which increased statistical differences. Unfortunately, the data were not sufficient to draw solid conclusions.

Our meta-analysis had some limitations. First, during the literature evaluation, we found that certain studies did not describe the randomization process or the procedure of allocation concealment in detail; therefore, we could not completely exclude selection bias. Second, the sample size was small in some of the studies and the term of treatment was short. Third, TGs were extracted from the traditional Chinese medicine, TwHF, which is not commonly prescribed in other countries. Therefore, all the selected studies in this meta-analysis were Chinese-based, which may have caused regional, language, and racial biases. Finally, some studies paid little attention to side effects, which may have led to unreliable conclusions. The data were not sufficient to draw solid conclusions. We await future RCTs to further provide reliable data.

Conclusions {#sec5}
===========

In conclusion, ACE inhibitors or ARBs plus TGs produce greater reductions in 24-h UTP and SCr levels in patients with DN than ACE inhibitors or ARBs alone, and even better effects might be achieved after long-term administration. There were no differences in side effects between ACE inhibitors or ARBs plus TGs and ACE inhibitors or ARBs alone. Thus, ACE inhibitors or ARBs administered together with TGs might improve the treatment of patients with impaired renal function.
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[^1]: TG: Tripterygium glycoside; ACEI: angiotensin-converting enzyme inhibitor; ARBs: angiotensin receptor blockers; ACEI/ARBs: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; tid: 3 times daily; bid: 2 times daily; qd: once a day; 24-h UTP: 24-h urine total protein quantitation; SCr: serum creatinine.

[^2]: In the ACEI/ARBs + TG group, four patients dropped out. Two were excluded because they were not strictly prescribed according to the doctor\'s orders and two were rejected because of missing visits; in the ACEI/ARBs group, five patients dropped out. One was excluded because they were not strictly prescribed according to the doctor\'s orders, one was rejected because of missing visits and three dropped out without reason.

[^3]: Two patients dropped out in the ACEI/ARB group because of repeated hyperkalemia; one patient dropped out in the ACEI/ARBs + TG group because of increased alanine aminotransferase.

[^4]: M/F: male/female; UTP: urine total protein; SCr: serum creatinine; ACEI: angiotensin-converting enzyme inhibitor; ARBs: angiotensin receptor blockers; TG: Tripterygium glycoside.
